Considerations in Weaning or Withdrawing Dupilumab Therapy—Nothing Is Forever

Lio expresses insights about considerations in weaning or withdrawing dupilumab therapy. The biologic revolution finally arrived for atopic dermatitis (AD) in 2017, with the approval of dupilumab, heralding a new era with many other agents in active development. Significant improvement in disease severity measures and a number of quality-of-life measures have raised the bar for AD treatment, mirroring the more stringent treatment goals that have been defined for patients with psoriasis.